Physician profile
Alejandro Perez
NPI 1598768301
$1,104.44
in general payments reported to CMS, 2019-2025
21 companies · $90.74 in 2025
The $90.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $166 · 2021: $280 · 2022: $95.30 · 2023: $140 · 2024: $73.98 · 2025: $90.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.88 | 2019-2023 | |
| Novo Nordisk INC | $116.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $108.04 | 2020-2024 | |
| Glaxosmithkline, LLC. | $92.69 | 2020-2021 | |
| Pfizer INC. | $77.30 | 2019-2020 | |
| Abbott Laboratories | $74.79 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $59.63 | 2019-2021 | |
| Lilly USA, LLC | $50.85 | 2019-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.16 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $40.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.82 | 2019-2020 | |
| Amgen INC. | $35.24 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $30.95 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $26.49 | 2019 | |
| Axsome Therapeutics, INC. | $22.45 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $18.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2021 | |
| Genentech USA, INC. | $14.99 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.92 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $12.73 | 2021 | |
| Eisai INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.